


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177 and Bond code: 40150)

PROFIT WARNING

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 37.47B(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors of the Company (the “**Board**”) would like to inform the securities holders of the Company and potential investors that as the financial performance of an associate was not as good as that in the same period last year, the Group’s profit attributable to the owners of the parent for the six months ended 30 June 2022 decreased by up to approximately 78% over the same period last year to approximately RMB1,871 million. While the Group’s share of profit of the associate decreased, the principal business of the Group performed as expected during the period, with steady growth in results year-on-year.

The Company is still in the process of finalizing its interim results for the six months ended 30 June 2022. The financial information contained in this announcement is solely based on a preliminary assessment by the management of the Company on the Company’s existing consolidated management accounts and is subject to finalization and adjustment, if any. Details of the financial information will be disclosed in the interim results announcement to be published by the Company on 23 August 2022.

Securities holders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 11 August 2022

As at the date of this announcement, the Board of the Company comprises eight executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.